Big Hurdles Keep Blood Cancer Drugs Out of Patients' Hands

A new nationwide study looked at how often patients with blood cancers could get specialty oral anticancer medications. The researchers examined 12,134 insured patients, most of them covered by Medicare and a smaller group by private plans. The big surprise was that very few patients actually received the medicine right away.

When a doctor wrote a prescription, insurers often said no. About 65% of Medicare prescriptions and 84% of commercial ones were rejected at first. The main reasons were prior authorization requirements and strict formulary rules. Even when a prescription passed, many patients never picked up the drug. Only 9.6% of Medicare patients and 4% of commercially insured patients filled their first prescription.

After 90 days, more prescriptions were approved, but the picture stayed grim. Roughly 85% of Medicare prescriptions and 63% of commercial ones eventually got the green light. Still, a large share of those approved prescriptions went unfilled. The final numbers were 54.5% for Medicare and 45.5% for commercial patients who both got approval and filled the script. High out‑of‑pocket costs killed fill rates. When patients had to pay more than $175, the chance of filling dropped sharply. The worst drop appeared at $500‑$2,000 for Medicare patients (about 29%) and at $2,000 or more for commercial patients (about 22%).

The study shows that both insurer restrictions and price barriers keep life‑saving drugs out of reach. Even after a prescription clears the payer's desk, many patients still cannot afford to fill it. Addressing prior authorization rules and making the drugs more affordable are key steps to improve treatment access for blood cancer patients.